In contrast, CDKN2A loss has been reported in as many as 94% of AN.16,19 Taken together, these findings support a model in which CDKN2A loss occurs during the transition from benign PN to AN, whereas TP53, EGFR, and SUZ12 alterations promote evolution to MPNST (Figure 2). This evidence concerns the gene TP53 and malignant peripheral nerve sheath tumor.